Analysts expect Qorvo, Inc. (NASDAQ:QRVO) to report $0.95 EPS on August, 7.They anticipate $0.15 EPS change or 18.75% from last quarter’s $0.8 EPS. QRVO’s profit would be $112.16M giving it 19.72 P/E if the $0.95 EPS is correct. After having $1.14 EPS previously, Qorvo, Inc.’s analysts see -16.67% EPS growth. The stock increased 0.25% or $0.19 during the last trading session, reaching $74.92. About 706,296 shares traded. Qorvo, Inc. (NASDAQ:QRVO) has declined 10.19% since July 28, 2018 and is downtrending. It has underperformed by 14.62% the S&P500. Some Historical QRVO News: 13/03/2018 Qorvo® Introduces lndustry’s Most Powerful GaN-on-SiC Transistor; 23/05/2018 – Qorvo Authorizes $1B Shr Repurchase Program; 30/05/2018 – Qorvo Presenting at Bank of America Conference Jun 6; 02/05/2018 – Qorvo Sees 1Q EPS 75c; 23/05/2018 – Qorvo Dismisses Auditor KPMG And Hires Ernst & Young Instead — MarketWatch; 23/05/2018 – Qorvo: Appoints Ernst & Young as Independent Registered Public Accounting Firm; 23/05/2018 – Qorvo Announces $1 Billion Share Repurchase Program; 18/04/2018 – Qorvo® to Webcast Quarterly Earnings Conference Call on May 2, 2018; 22/04/2018 – DJ Qorvo Inc, Inst Holders, 1Q 2018 (QRVO); 24/04/2018 – MicroDevices Expands Fabrication Capability with High Rate Etcher
Advanta Home Equity Loan Trust 1993-3 (IART) investors sentiment increased to 1.27 in 2019 Q1. It’s up 0.06, from 1.21 in 2018Q4. The ratio improved, as 112 hedge funds increased and opened new equity positions, while 88 cut down and sold their stock positions in Advanta Home Equity Loan Trust 1993-3. The hedge funds in our database now own: 69.24 million shares, down from 70.91 million shares in 2018Q4. Also, the number of hedge funds holding Advanta Home Equity Loan Trust 1993-3 in top ten equity positions increased from 1 to 2 for an increase of 1. Sold All: 18 Reduced: 70 Increased: 73 New Position: 39.
Qorvo, Inc. provides radio frequency solutions and technologies for mobile device, infrastructure, and defense and aerospace applications worldwide. The company has market cap of $8.85 billion. It operates through Mobile Products (MP) and Infrastructure and Defense Products (IDP) divisions. It has a 71.35 P/E ratio. The MP segment offers cellular RF and WiFi solutions, bulk acoustic wave (BAW) and surface acoustic wave (SAW) filters, power amplifiers (PA), low noise amplifiers, switches, multi-band PAs and transmit modules, RF power management integrated circuits, diversity receive modules, antenna switch modules, antenna tuning and control solutions, modules incorporating PAs and duplexers, and modules incorporating switches, PAs, and duplexers.
Among 3 analysts covering Qorvo (NASDAQ:QRVO), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Qorvo had 10 analyst reports since February 8, 2019 according to SRatingsIntel. On Monday, March 4 the stock rating was maintained by Needham with “Buy”. The stock of Qorvo, Inc. (NASDAQ:QRVO) earned “Hold” rating by Canaccord Genuity on Friday, February 8. KeyBanc Capital Markets upgraded it to “Overweight” rating and $85 target in Tuesday, April 2 report.
More notable recent Qorvo, Inc. (NASDAQ:QRVO) news were published by: Finance.Yahoo.com which released: “Here’s What We Think About Qorvo, Inc.’s (NASDAQ:QRVO) CEO Pay – Yahoo Finance” on July 01, 2019, also Nasdaq.com with their article: “Qorvo® to Webcast Quarterly Earnings Conference Call on August 1, 2019 – Nasdaq” published on July 18, 2019, Finance.Yahoo.com published: “Stocks – Markets Rise on Hopes for a Trade Deal – Yahoo Finance” on July 01, 2019. More interesting news about Qorvo, Inc. (NASDAQ:QRVO) were released by: Investorplace.com and their article: “10 Small-Cap, Up-And-Coming Stocks to Keep on Your Radar – Investorplace.com” published on July 24, 2019 as well as Finance.Yahoo.com‘s news article titled: “Should We Be Cautious About Qorvo, Inc.’s (NASDAQ:QRVO) ROE Of 3.1%? – Yahoo Finance” with publication date: June 04, 2019.
The stock increased 1.82% or $1.13 during the last trading session, reaching $63.27. About 381,919 shares traded. Integra LifeSciences Holdings Corporation (IART) has declined 20.92% since July 28, 2018 and is downtrending. It has underperformed by 25.35% the S&P500. Some Historical IART News: 25/04/2018 – FDA: Roche Diagnostics Corporation- Roche Acetaminophen assay 03255379160-HAcetaminophen (P) 20767174160- cobas c Integra; 11/04/2018 – Taylor & Francis Group Selects Integra Software Services as Their Core Full-service Production Partner for Global Journal Conte; 22/03/2018 – MITEL REPORTS PACT TO SELL DETEWE TO GERMAN ICT SYSTEMS INTEGRA; 25/04/2018 – INTEGRA LIFESCIENCES SEES FY ADJ EPS $2.34 TO $2.42, EST. $2.33; 25/04/2018 – INTEGRA LIFESCIENCES BOOSTS FORECAST; 17/04/2018 – Integra Connect Launches Advanced Analytics Suite to Help Oncology Practices Improve Cost-Efficiency and Quality of Value-Based; 08/05/2018 – BBG BUYS INTEGRA REALTY RESOURCES OFFICES IN PACIFIC NORTHWEST; 25/04/2018 – INTEGRA LIFESCIENCES 1Q REV. $357.1M, EST. $349.2M; 25/04/2018 – INTEGRA LIFESCIENCES HOLDINGS SAYS RAISING FULL-YEAR 2018 ADJUSTED EARNINGS PER SHARE TO $2.34 TO $2.42; 25/04/2018 – Integra LifeSciences 1Q Adj EPS 58c
Champlain Investment Partners Llc holds 2.66% of its portfolio in Integra LifeSciences Holdings Corporation for 5.47 million shares. Falcon Point Capital Llc owns 80,729 shares or 2.45% of their US portfolio. Moreover, Tributary Capital Management Llc has 2.06% invested in the company for 508,838 shares. The New York-based Broadfin Capital Llc has invested 1.63% in the stock. Mesirow Financial Investment Management, a Alabama-based fund reported 182,585 shares.
Integra LifeSciences Holdings Corporation develops, makes, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company has market cap of $5.41 billion. The firm operates through two divisions, Specialty Surgical Solutions; and Orthopedics and Tissue Technologies. It has a 54.31 P/E ratio. It offers neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.